AKBA
NASDAQ
US
Akebia Therapeutics, Inc. - Common Stock
$1.38
▼ $-0.03
(-2.13%)
Vol 1.9M
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$427.2M
ROE
21.7%
Margin
-7.1%
D/E
461.45
Beta
0.40
52W
$1–$4
Wall Street Consensus
11 analysts · Apr 20265
Strong Buy
5
Buy
1
Hold
0
Sell
0
Strong Sell
90.9%
Buy Rating
Price Chart
Similar Stocks
About Akebia Therapeutics, Inc. - Common Stock
Earnings
Beat rate: 75.0%
Next Report
May 06, 2026
EPS Estimate: $-0.03
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.03 | — | — |
| Dec 2025 | $-0.03 | $-0.05 | $-0.02 |
| Sep 2025 | $-0.02 | $0.00 | +$0.02 |
| Jun 2025 | $-0.02 | $0.00 | +$0.02 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $46.5M | $57.3M | $62.5M | $58.8M | $57.6M |
| Net Income | — | -$22.8M | $6.1M | $247K | $540K | -$12.2M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 23.6% | 23.6% | 23.6% | 23.6% | 21.7% | 21.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | 0.4% | -17.9% | -17.9% | -17.9% | -7.1% | -7.1% |
| Gross Margin | 82.5% | 83.2% | 83.2% | 83.2% | 82.5% | 82.5% |
| D/E Ratio | 641.41 | 161.04 | 641.41 | 641.41 | 461.45 | 461.45 |
| Current Ratio | 1.98 | 1.98 | 1.98 | 1.98 | 1.94 | 1.94 |
Key Ratios
ROA (TTM)
-5.1%
P/S (TTM)
1.90
P/B
20.0
EPS (TTM)
$-0.08
CF/Share
$-0.13
Rev Growth 3Y
-8.9%
52W High
$4.08
52W Low
$1.45
$1.45
52-Week Range
$4.08
Financial Health
Free Cash Flow
$23.3M
Net Debt
-$133.0M
Cash
$184.8M
Total Debt
$51.8M
As of Dec 31, 2025
How does AKBA compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
AKBA valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
1.9
▼
85%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
20.0
▲
714%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
AKBA profitability vs Biotechnology peers
ROE
21.7%
▲
132%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-7.1%
▲
98%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
82.5%
▲
5%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-5.1%
▲
89%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
AKBA financial health vs Biotechnology peers
D/E ratio
461.5
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
1.9
▼
56%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.4
▼
59%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
AKBA fundamentals radar
AKBA
Peer median
Industry
AKBA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
AKBA vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
BUTLER JOHN P
Chief Executive Officer · Mar 04
69270 shs
BURKE STEVEN KEITH
Officer · Feb 02
67658 shs
BUTLER JOHN P
Chief Executive Officer · Feb 02
341305 shs
GRUND NICHOLAS
Officer · Feb 02
84829 shs
OSTROWSKI ERIK
Chairman of the Board · Feb 02
34951 shs
MALABRE RICHARD C.
Officer · Feb 02
49524 shs
RUCCI CAROLYN M
Officer · Feb 02
69772 shs
BUTLER JOHN P
Chief Executive Officer · Feb 02
175250 shs
MALABRE RICHARD C.
Officer · Jan 30
79000 shs
RUCCI CAROLYN M
Officer · Jan 30
190000 shs
Last 90 days
Top Holders
Top 5: 22.4%Blackrock Inc.
7.21%
$25.9M
Vanguard Group Inc
5.98%
$21.5M
State Street Corporation
5.11%
$18.3M
Geode Capital Management, L…
2.34%
$8.4M
Goldman Sachs Group Inc
1.76%
$6.3M
As of Dec 31, 2025
Latest News
No related news yet